John O. Mascarenhas, MD

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.

A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.

A broader overview of the role that JAK inhibitors play in patients with myelofibrosis and how that role has continued to evolve in the current treatment paradigm.

Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy.

Expert panelists share brief insight on the current NCCN guidelines for selecting treatment in patients with myelofibrosis.

Focused discussion on the factors that help to select patients for stem cell transplantation over systemic therapy in the setting of myelofibrosis.

A comprehensive discussion on the respective role stem cell transplantation has in the treatment armamentarium for myelofibrosis.

Key opinion leaders in myelofibrosis management reflect on the role of biomarkers in informing treatment selection, even for patients with triple-negative disease.

Shared insight from a panel of experts on the current state of cytogenetics in myelofibrosis and how it impacts treatment pathways for patients.

Expert panelists provide an overview of the signs and symptoms indicative of myelofibrosis and consider factors that help to inform prognostication.

The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.

Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.

A look at sequencing strategies for myelofibrosis treatments.

Dr Srdan Verstovsek shares how he assesses myelofibrosis treatment response in his clinical practice.

Raajit Rampal, MD, explains how he considers safety profiles when deciding on appropriate treatment for myelofibrosis and how he manages toxicities for patients.

A discussion on when to switch a patient with myelofibrosis to a new JAK inhibitor treatment, and possible strategies for transitioning.

John Mascarenhas, MD, presents a clinical scenario of a 73-year-old man with myelofibrosis and a low platelet count.

A panel of experts considers treatment options for patients with myelofibrosis based on platelet counts, while factoring in health insurance barriers.

Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.

A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.

Dr John Mascarenhas presents a patient case scenario of a 68-year-old woman with a common presentation of primary myelofibrosis.

Raajit Rampal, MD, describes the JAK-STAT pathway and how it’s fundamental to all types of myelofibrosis.

Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.

Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.

Responses to questions by community hematologists/oncologists regarding optimal ways to diagnose and manage patients with myelofibrosis.

Clinical pearls for planning and sequencing therapy for patients with myelofibrosis.

Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.